The effect of montelukast on soluble interleukin-2 receptor and tumor necrosis factor alpha in pediatric asthma

Proinflammatory cytokines such as tumor necrosis factor (TNF) alpha and soluble interleukin 2 receptor (sIL-2R) are very important mediators in induction of inflammatory response in lung. The aim of this study was to investigate anti-inflammatory response of cysteinyl leukotriene receptor antagonist montelukast on macrophage and T-cell activation by sIL-2R and TNF-alpha in mild atopic asthmatic children. Fifteen children with mild-to-moderate atopic asthma and 15 nonatopic children as control, enrolled in the study. Asthmatic children were treated with montelukast, 5-mg tablets for 1 month. Lung function test forced expiratory volume in 1 second (FEV1) was performed before and after treatment. Serum TNF-alpha, sIL-2R, and eosinophil cationic protein levels were determined in the control group and in asthmatic children before and after treatment. The mean eosinophil cationic protein value was significantly decreased (33.1 +/- 14.8 and 22.2 +/- 12.1; p < 0.05) and FEV1 was significantly increased (86.9 +/- 20.9 and 102.1 +/- 12.7, p < 0.05) after 1 month treatment with montelukast. The mean serum IL-2R levels were significantly higher in the before treatment group than in the after treatment group (1061.9 +/- 491 and 794 +/- 230.9; p < 0.05) or in control subjects (581.1 +/- 123; p < 0.01). The mean serum TNF-alpha level was higher in the before treatment group than in the after treatment group and control group (7.30 +/- 3.93, 5.20 +/- 1.46, and 4.95 +/- 1.27, p < 0.05). There was a significant correlation between TNF-a and sIL-2R in patients before montelukast treatment (r = 0.674; p < 0.01). This study indicates that montelukast improves clinical parameters and shows anti-inflammatory response by decreasing serum sIL-2R and TNF-alpha levels.

Yazar Can, Murat
Yuksel, Birol
Demirtas, Selda
Tomac, Nazan
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3516
Tek Biçim Adres 10.2500/aap.2006.27.2923
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı ALLERGY AND ASTHMA PROCEEDINGS
Dergi Cilt Bilgisi 27
Dergi Sayısı 4
Sayfalar 383 - 386
Yayın Yılı 2006
Eser Adı
[dc.title]
The effect of montelukast on soluble interleukin-2 receptor and tumor necrosis factor alpha in pediatric asthma
Yazar
[dc.contributor.author]
Can, Murat
Yazar
[dc.contributor.author]
Yuksel, Birol
Yazar
[dc.contributor.author]
Demirtas, Selda
Yazar
[dc.contributor.author]
Tomac, Nazan
Yayın Yılı
[dc.date.issued]
2006
Yayıncı
[dc.publisher]
OCEAN SIDE PUBLICATIONS INC
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Proinflammatory cytokines such as tumor necrosis factor (TNF) alpha and soluble interleukin 2 receptor (sIL-2R) are very important mediators in induction of inflammatory response in lung. The aim of this study was to investigate anti-inflammatory response of cysteinyl leukotriene receptor antagonist montelukast on macrophage and T-cell activation by sIL-2R and TNF-alpha in mild atopic asthmatic children. Fifteen children with mild-to-moderate atopic asthma and 15 nonatopic children as control, enrolled in the study. Asthmatic children were treated with montelukast, 5-mg tablets for 1 month. Lung function test forced expiratory volume in 1 second (FEV1) was performed before and after treatment. Serum TNF-alpha, sIL-2R, and eosinophil cationic protein levels were determined in the control group and in asthmatic children before and after treatment. The mean eosinophil cationic protein value was significantly decreased (33.1 +/- 14.8 and 22.2 +/- 12.1; p < 0.05) and FEV1 was significantly increased (86.9 +/- 20.9 and 102.1 +/- 12.7, p < 0.05) after 1 month treatment with montelukast. The mean serum IL-2R levels were significantly higher in the before treatment group than in the after treatment group (1061.9 +/- 491 and 794 +/- 230.9; p < 0.05) or in control subjects (581.1 +/- 123; p < 0.01). The mean serum TNF-alpha level was higher in the before treatment group than in the after treatment group and control group (7.30 +/- 3.93, 5.20 +/- 1.46, and 4.95 +/- 1.27, p < 0.05). There was a significant correlation between TNF-a and sIL-2R in patients before montelukast treatment (r = 0.674; p < 0.01). This study indicates that montelukast improves clinical parameters and shows anti-inflammatory response by decreasing serum sIL-2R and TNF-alpha levels.
Açıklama
[dc.description]
WOS: 000240040700014
Açıklama
[dc.description]
PubMed: 16948354
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1088-5412
İlk Sayfa Sayısı
[dc.identifier.startpage]
383
Son Sayfa Sayısı
[dc.identifier.endpage]
386
Dergi Adı
[dc.relation.journal]
ALLERGY AND ASTHMA PROCEEDINGS
Dergi Sayısı
[dc.identifier.issue]
4
Dergi Cilt Bilgisi
[dc.identifier.volume]
27
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.2500/aap.2006.27.2923
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3516
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
24
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
04 Şubat 2024 03:09
Google Kontrol
Tıklayınız
treatment montelukast children before sIL-2R TNF-alpha control significantly response levels atopic higher asthmatic anti-inflammatory receptor protein cationic eosinophil increased Proinflammatory correlation decreasing parameters clinical improves indicates patients between significant subjects performed mediators antagonist leukotriene cysteinyl
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms